Internal Server Error

Predicta Biosciences - About the company

Predicta Biosciences is a series A company based in Boston (United States), founded in 2023 by Gad Getz, Irene Ghobrial and Ken Anderson. It operates as a Provider of diagnostic and therapeutic products for oncology. Predicta Biosciences has raised $28.6M in funding from Engine Ventures. The company has 102 active competitors, including 39 funded and 14 that have exited. Its top competitors include companies like Personalis, Epredia and Angle.

Company Details

Provider of diagnostic and therapeutic products for oncology. It offers a non-invasive diagnostics focus on multiple myeloma and evaluate patients’ immune system cells to determine the patient responding to immunotherapies.
Key Metrics
Founded Year
2023
Location
Boston, United States
Stage
Series A
Total Funding
$28.6M in 2 rounds
Latest Funding Round
Ranked
Employee Count
22 as on Sep 30, 2026
Similar Companies
Sign up to download Predicta Biosciences' company profile

Predicta Biosciences's funding and investors

Predicta Biosciences has raised a total funding of $28.6M over 2 rounds. Its first funding round was on Jul 16, 2024. Its latest funding round was a Series A round on Oct 01, 2025 for $*****. 6 investors participated in its latest round. Predicta Biosciences has 9 institutional investors.

Here is the list of recent funding rounds of Predicta Biosciences:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Oct 01, 2025
9906132
Series A
3616073
3937965
9784261
6679625
Jul 16, 2024
4042367
Seed
4739817
3992997
lockAccess funding benchmarks and valuations. Sign up today!

Predicta Biosciences' founders and board of directors

Founder? Claim Profile
The founders of Predicta Biosciences are Gad Getz, Irene Ghobrial and Ken Anderson. Kate Caves is the CEO of Predicta Biosciences.
Here are the details of Predicta Biosciences' key team members:

Predicta Biosciences' employee count trend

Predicta Biosciences has 22 employees as of Sep 26. Here is Predicta Biosciences's employee count trend over the years:
Employee count trend for Predicta Biosciences
lockUncover Predicta Biosciences' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Predicta Biosciences's Competitors and alternates

Top competitors of Predicta Biosciences include Personalis, Epredia and Angle. Here is the list of Top 10 competitors of Predicta Biosciences, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Personalis
Personalis
2011, Menlo Park (United States), Acquired
Provider of genomic sequencing and diagnosis software for the healthcare industry
$87.3M
68/100
2nd
Logo for Predicta Biosciences
Predicta Biosciences
2023, Boston (United States), Series A
Provider of diagnostic and therapeutic products for oncology
$28.6M
59/100
3rd
Logo for Epredia
Epredia
2019, United Kingdom, Unfunded
Developer of in-vitro diagnostic test for cancer
-
-
58/100
4th
Logo for Angle
Angle
1994, Surrey (Canada), Public
Developer of cancer cell capture and analysis equipment
-
57/100
5th
Logo for Xcell Biosciences
Xcell Biosciences
2012, San Francisco (United States), Series B
Developer of cell culture analysis device for cancer research
$40.9M
56/100
6th
Logo for Strata Oncology
Strata Oncology
2015, Ann Arbor (United States), Series C
Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms
$139M
53/100
7th
Logo for ACT Genomics
ACT Genomics
2014, Taipei (Taiwan), Acquired
Clinical and research services in genomics for cancer
$20.5M
52/100
8th
Logo for OncoPrecision
OncoPrecision
2020, Cordoba (Argentina), Seed
Developer of personalized assays for oncology precision therapy
$4.2M
51/100
9th
Logo for Ultivue
Ultivue
2015, Cambridge (United States), Series D
Provider of test panels for personalized cancer therapies
$105M
51/100
10th
Logo for PierianDx
PierianDx
2014, Saint Louis (United States), Acquired
Provider of genetic tests for individualized diagnosis of multiple diseases
$69.4M
50/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Predicta Biosciences's competitors? Click here to see the top ones

Predicta Biosciences's Investments and acquisitions

Predicta Biosciences has made no investments or acquisitions yet.

Reports related to Predicta Biosciences

Here is the latest report on Predicta Biosciences's sector:

News related to Predicta Biosciences

Media has covered Predicta Biosciences for a total of 3 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
Predicta Biosciences Completes $23.4 Million Series A Financing RoundGlobal Legal Chronicle•Oct 09, 2025•Predicta Biosciences
•
•
Predicta Biosciences Launches First Molecular Diagnostic ProductBusiness Wire•Apr 30, 2025•Predicta Biosciences
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Predicta Biosciences

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford